HARMONi-7NCT06767514
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 274 → 285 locations
- Eligibility criteria expanded, about 19 words
- Secondary endpoints: details revised at 1 of 4 entries
- Minor Trial sites expanded: 270 → 274 locationsv10
- Minor Trial sites expanded: 202 → 270 locationsv9
- Minor Study sites: 120 to 202v8
- Minor Study sites: 94 to 120v7
Show 5 earlier versionsHide 5 earlier versions
- Minor Study sites: 74 to 94v6
- Minor Study sites: 45 to 74v5
- Minor Study sites: 23 to 45v4
- Minor Study sites: 3 to 23
- Start date changed from estimate of Jan 2025 to Feb 27, 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 3
- Start date: Dec 31, 2024 to Jan 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Overall Survival (OS)
Timeframe: Up to approximately 36 months
Progression free survival (PFS)
Timeframe: Up to approximately 36 months
Secondary (4)
Objective response rate (ORR)
Disease control rate ( DCR)
Duration of response (DoR)
Adverse Events (AE): incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results
Arms and interventions
Arm A - IvonescimabExperimental
Subject will receive ivonescimab as an IV injection
Arm B - PembrolizumabActive comparator
Subject will receive pembrolizumab as an IV injection
Biologicals: Ivonescimab Injection, Pembrolizumab Injection
Sites
285 sites in 17 countries
United States 97, China 34, Spain 25, Japan 20, Turkey (Türkiye) 17, Mexico 15, France 14, Romania 11, Italy 10, Germany 9, Greece 6, Portugal 6, Hungary 5, Poland 5, Canada 4, Serbia 4, Belgium 3